Status:
COMPLETED
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Lead Sponsor:
National Cancer Centre, Singapore
Collaborating Sponsors:
National Medical Research Council (NMRC), Singapore
Conditions:
Metastatic Triple-Negative Breast Carcinoma
Eligibility:
FEMALE
21+ years
Phase:
PHASE1
Brief Summary
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. Cell state transitions, e.g. epithelial-to-mesenc...
Eligibility Criteria
Inclusion
- Patients with histologically or cytologically proven metastatic TNBC
- Patients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil
- Females aged 21 years and older
- ECOG performance status 0 or 1
- Life expectancy greater than three months
- Patients have normal organ and marrow function
- Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment
Exclusion
- Previous palliative radiotherapy to potentially biopsy-able lesion
- Active symptomatic central nervous system (CNS) metastases
- Spinal cord compression not definitively treated with surgery and/or radiation
- Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2025
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04664829
Start Date
October 1 2020
End Date
August 4 2025
Last Update
September 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center Singapore
Singapore, Singapore, 168583